

For Immediate Release

**PluroGen Therapeutics, Inc. Announces**

**226 Patient Clinical Paper Reporting Success for PluroGel® PSSD is Published**

Norristown, Pennsylvania, 09 September 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that the 226 Patient Clinical Paper Reporting Success for PluroGel® PSSD was published by one of the world's leading wound care clinical journals, the *International Wound Journal*.

The Abstract for the paper can be found at:

The *International Wound Journal* Website: <http://onlinelibrary.wiley.com/doi/10.1111/iwj.12361/abstract>

or

The PubMed Website: <http://www.ncbi.nlm.nih.gov/pubmed/?term=Efficacy+of+a+new+multifunctional+surfactant-based+biomaterial+dressing+with+1%25+silver+sulphadiazine+in+chronic+wounds>

The patient results reported in this paper are better than published results the Company is aware of for any other product:

This paper reports a 73% wound healing rate when the doctor immediately starts with PluroGel PSSD: This 73% wound healing rate is much better than the published healing rates for competitive products.

This paper reports many other benefits of using the Company's advanced surfactant-based PluroGel Biomaterial.

Publication of this paper is a major milestone for PluroGel® PSSD Burn and Wound Dressing because it is a scientifically peer-reviewed complete clinical study published in a major journal.

"For PluroGel® PSSD Burn and Wound Dressing to have such a significant scientific support document is an important step forward and valuable asset" commented Neal Koller, President and CEO of PluroGen. "This article is a valuable tool to support PluroGel® PSSD product use and sales and to support product reimbursement from insurance companies and government payers".

**About PluroGen Therapeutics**

PluroGen Therapeutics, Inc. is a biotechnology company that provides clinically advanced topical anti-infective products for diabetic ulcers, chronic (nonhealing) wounds and burns. The company developed its core family of PluroGel® products by utilizing its patent-protected advanced PluroGel® Biomaterial. In working closely with doctors, nurses, patients and healthcare institutions, PluroGel® products have been routinely used with documented superior results on more than 14,000 patients in and outside of the USA. More information can be found on the company web site at [www.plurogen.com](http://www.plurogen.com). For PluroGen Investor Information please call +1 (610) 539-3670.

**Safe Harbor Statement:**

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.